G. Lenaz

An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.

C. Henry, S. Fiocchi, K. Selting, 2011, Journal of veterinary internal medicine.

Adriamycin cardiotoxicity: a survey of 1273 patients.

H. von Melchner, H. Senn, G. Bonadonna, 1979, Cancer treatment reports.

A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.

F. Pannuti, P. Nanni, G. Lenaz, 1978, Cancer treatment reports.

Effect of micronutrient status on natural killer cell immune function in healthy free-living subjects aged >/=90 y.

D. Cucinotta, E. Mariani, G. Ravaglia, 2000, The American journal of clinical nutrition.

PHASE II MARKER LESION STUDY WITH INTRAVESICAL INSTILLATION OF EOQUIN TM IN SUPERFICIAL BLADDER CANCER, TOXICITY AND MARKER RESPONSE - THE FINAL RESULTS

J. Witjes, T. Reijke, H. Vergunst, 2006 .

Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.

A. Scally, R. Phillips, G. Lenaz, 2009, Urology.

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

J. Beijnen, J. Double, P. Loadman, 2006, The Journal of urology.

Analysis of NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression suggests a possible role for EO9 in the treatment of invasive bladder cancer

R. Wheelhouse, D. Mirejovsky, R. Phillips, 2006 .